Hims & Hers Delivers Huge Growth Despite Stock Drop

Hims & Hers - our best performing pick ever - reported another outstanding quarter and fiscal year. For the year, revenues were up 69%, with Q4 coming in 95% higher than the comparable quarter last year - its fastest growth quarter of the year. The company has a lot of momentum. Monthly revenue per subscriber was up 19% of the year, 38% for the quarter. HIMS ended the year with 2.2 million subscribers, a 45% increase over last year. Yes, I know the stock has plummeted from $70 down to the low $40's, but the $70 number was just market foolishness over GLP hype. The truth is that less than 15% of Hims & Hers business is GLP drugs, and the company grew revenue 43% even taking that out entirely. With my new (and greatly raised) $35 price target, where it trades now is approaching fair value. This is going to be a wild ride, and my plan is to just ride it out. The trajectory should be up - way up - over time. Let your winners ride!

Watch List

APPF -3.02%
CMG 43.83%
VEEV 16.09%
INTU 19.56%
WDAY -7.52%
PSTG -0.65%
RDDT 18.10%
NTNX 24.37%
CRWD 94.01%
SE 26.50%
SNOW 13.14%

Buy List

PINS -36.44%
SEMR -33.35%
TSM -40.82%
ZETA -27.00%
GOOG -49.43%
NYAX -28.98%
MSFT -28.62%
ODD -29.76%
FLYW -42.32%
HRMY -59.44%
YOU -38.27%
ABNB -31.17%
ADBE -42.81%

Hold List

ASML -22.86%
VTEX -14.24%
ASR -23.26%
CELH 46.96%
TOST 20.33%
CPNG -11.55%
HIMS -19.74%
PAYC -18.13%
MNDY 18.61%
GLBE -21.26%
ZS 32.26%
V -7.16%
ADSK -0.03%
NOW 14.16%
MELI -23.30%
FTNT -0.20%
TEAM 0.30%